Jeffrey Mulhern - Concepedia

Author

Jeffrey Mulhern

Baystate Medical Center

Also Known As

J G Mulhern, J Muir, J Mulhern, J. G. Mulhern, JEFFREY Mulhern, Jeffrey G. Mulhern, Jeffrey Mulhern

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Baystate Medical Center Tufts University Stanford University Brigham and Women's Hospital Pioneer (United States)

About

Jeffrey Mulhern is an author at Baystate Medical Center specializing in medicine, nephrology, and hemodialysis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	665
2	Health Sciences	2	2	209
3	Allergy	1	1	19
4	Applied Physiology	1	1	194
5	Cardiothoracic Surgery	1	1	21

Jeffrey Mulhern

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Changing incidence of glomerular diseases in adults Gregory L. Braden, Jeffrey Mulhern, Michael H. O’Shea, American Journal of Kidney Diseases Glomerular DiseaseGlomerulonephritisHemodialysisGlomerular DiseasesRenal Disease	2000	257
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy Jonathan Barratt, Richard Lafayette, Jens Kristensen, Kidney International	2022	205
Resistance training improves strength and functional measures in patients with end-stage renal disease Samuel Headley, Michael J. Germain, Patrick Mailloux, American Journal of Kidney Diseases Strength TrainingRenal FunctionKinesiologyExerciseApplied Physiology	2002	194
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial PK Judge, Natalie Staplin, KJ Mayne, The Lancet Diabetes & Endocrinology	2023	88
Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients Jeffrey Mulhern, Gregory L. Braden, Michael H. O’Shea, American Journal of Kidney Diseases HemodialysisUrologyMedicinePeritoneal Dialysis PatientsRenal Pathology	1995	71
Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients Robert L. Madden, Jeffrey Mulhern, Bernard Benedetto, Transplant International	2000	42
Acute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors G. L. Braden, Michael H. O’Shea, Jeffrey Mulhern, Nephrology Dialysis Transplantation	2004	42
Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients Robert L. Madden, Jeffrey Mulhern, Bernard Benedetto, Transplant International Transplant RejectionUrologyTransplantationKidney TransplantKidney Transplantation	2000	41
Increased osmolal gap in alcoholic acidosis. G. L. Braden, C H Strayhorn, Michael J. Germain, PubMed Serum GlycerolAlcoholic AcidosisOsmolal GapMedicinePhysiology	1993	35
Long-term maintenance of therapeutic cyclosporine levels leads to optimal graft survival without evidence of chronic nephrotoxicity George S. Lipkowitz, Robert L. Madden, Jeffrey Mulhern, Transplant International	1999	22

Page 1